Laura Loughlin1, Thomas P Hellyer2, P Lewis White3, Danny F McAuley1, Andrew Conway Morris4, Raquel B Posso3, Malcolm D Richardson5, David W Denning6, A John Simpson2, Ronan McMullan1. 1. Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom. 2. Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. 3. Public Health Wales, Microbiology Cardiff, University Hospital of Wales, Heath Park, Cardiff, United Kingdom. 4. Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; and. 5. UK NHS Mycology Reference Centre, Manchester University NHS Foundation Trust and. 6. The University of Manchester and Manchester Academic Health Science Centre, National Aspergillosis Centre, Wythenshawe Hospital, Manchester, United Kingdom.
Abstract
Rationale: Aspergillus infection in patients with suspected ventilator-associated pneumonia remains uncharacterized because of the absence of a disease definition and limited access to sensitive diagnostic tests. Objectives: To estimate the prevalence and outcomes of Aspergillus infection in adults with suspected ventilator-associated pneumonia. Methods: Two prospective UK studies recruited 360 critically ill adults with new or worsening alveolar shadowing on chest X-ray and clinical/hematological parameters supporting suspected ventilator-associated pneumonia. Stored serum and BAL fluid were available from 194 nonneutropenic patients and underwent mycological testing. Patients were categorized as having probable Aspergillus infection using a definition comprising clinical, radiological, and mycological criteria. Mycological criteria included positive histology or microscopy, positive BAL fluid culture, galactomannan optical index of 1 or more in BAL fluid or 0.5 or more in serum.Measurements and Main Results: Of 194 patients evaluated, 24 met the definition of probable Aspergillus infection, giving an estimated prevalence of 12.4% (95% confidence interval, 8.1-17.8). All 24 patients had positive galactomannan in serum (n = 4), BAL fluid (n = 16), or both (n = 4); three patients cultured Aspergillus sp. in BAL fluid. Patients with probable Aspergillus infection had a significantly longer median duration of critical care stay (25.5 vs. 15.5 d, P = 0.02). ICU mortality was numerically higher in this group, although this was not statistically significant (33.3% vs. 22.8%; P = 0.23).Conclusions: The estimated prevalence for probable Aspergillus infection in this geographically dispersed multicenter UK cohort indicates that this condition should be considered when investigating patients with suspected ventilator-associated pneumonia, including patient groups not previously recognized to be at high risk of aspergillosis.
Rationale: Aspergillus infection in patients with suspected ventilator-associated pneumonia remains uncharacterized because of the absence of a disease definition and limited access to sensitive diagnostic tests. Objectives: To estimate the prevalence and outcomes of Aspergillus infection in adults with suspected ventilator-associated pneumonia. Methods: Two prospective UK studies recruited 360 critically ill adults with new or worsening alveolar shadowing on chest X-ray and clinical/hematological parameters supporting suspected ventilator-associated pneumonia. Stored serum and BAL fluid were available from 194 nonneutropenic patients and underwent mycological testing. Patients were categorized as having probable Aspergillus infection using a definition comprising clinical, radiological, and mycological criteria. Mycological criteria included positive histology or microscopy, positive BAL fluid culture, galactomannan optical index of 1 or more in BAL fluid or 0.5 or more in serum.Measurements and Main Results: Of 194 patients evaluated, 24 met the definition of probable Aspergillus infection, giving an estimated prevalence of 12.4% (95% confidence interval, 8.1-17.8). All 24 patients had positive galactomannan in serum (n = 4), BAL fluid (n = 16), or both (n = 4); three patients cultured Aspergillus sp. in BAL fluid. Patients with probable Aspergillus infection had a significantly longer median duration of critical care stay (25.5 vs. 15.5 d, P = 0.02). ICU mortality was numerically higher in this group, although this was not statistically significant (33.3% vs. 22.8%; P = 0.23).Conclusions: The estimated prevalence for probable Aspergillus infection in this geographically dispersed multicenter UK cohort indicates that this condition should be considered when investigating patients with suspected ventilator-associated pneumonia, including patient groups not previously recognized to be at high risk of aspergillosis.
Authors: Kirsten van de Groep; Diana M Verboom; Frank L van de Veerdonk; Pieter-Jan A Haas; Tom van der Poll; Marcus J Schultz; Marc J M Bonten; Olaf L Cremer Journal: Am J Respir Crit Care Med Date: 2019-09-01 Impact factor: 21.405
Authors: Wouter Meersseman; Stefaan J Vandecasteele; Alexander Wilmer; Eric Verbeken; Willy E Peetermans; Eric Van Wijngaerden Journal: Am J Respir Crit Care Med Date: 2004-06-30 Impact factor: 21.405
Authors: John W Baddley; Jennifer M Stephens; Xiang Ji; Xin Gao; Haran T Schlamm; Miriam Tarallo Journal: BMC Infect Dis Date: 2013-01-23 Impact factor: 3.090
Authors: Chadi A Hage; Eva M Carmona; Oleg Epelbaum; Scott E Evans; Luke M Gabe; Qusay Haydour; Kenneth S Knox; Jay K Kolls; M Hassan Murad; Nancy L Wengenack; Andrew H Limper Journal: Am J Respir Crit Care Med Date: 2019-09-01 Impact factor: 21.405
Authors: Thomas P Hellyer; Daniel F McAuley; Timothy S Walsh; Niall Anderson; Andrew Conway Morris; Suveer Singh; Paul Dark; Alistair I Roy; Gavin D Perkins; Ronan McMullan; Lydia M Emerson; Bronagh Blackwood; Stephen E Wright; Kallirroi Kefala; Cecilia M O'Kane; Simon V Baudouin; Ross L Paterson; Anthony J Rostron; Ashley Agus; Jonathan Bannard-Smith; Nicole M Robin; Ingeborg D Welters; Christopher Bassford; Bryan Yates; Craig Spencer; Shondipon K Laha; Jonathan Hulme; Stephen Bonner; Vanessa Linnett; Julian Sonksen; Tina Van Den Broeck; Gert Boschman; Dw James Keenan; Jonathan Scott; A Joy Allen; Glenn Phair; Jennie Parker; Susan A Bowett; A John Simpson Journal: Lancet Respir Med Date: 2019-12-03 Impact factor: 102.642
Authors: Robinder G Khemani; Jessica T Lee; David Wu; Edward J Schenck; Margaret M Hayes; Patricia A Kritek; Gökhan M Mutlu; Hayley B Gershengorn; Rémi Coudroy Journal: Am J Respir Crit Care Med Date: 2021-05-01 Impact factor: 21.405
Authors: Silvia Corcione; Tommaso Lupia; Stefania Raviolo; Giorgia Montrucchio; Alice Trentalange; Antonio Curtoni; Rossana Cavallo; Francesco Giuseppe De Rosa Journal: Intern Emerg Med Date: 2021-03-22 Impact factor: 3.397
Authors: Andrew Conway Morris; Katharina Kohler; Thomas De Corte; Maurizio Cecconi; Jan De Waele; Ari Ercole; Harm-Jan De Grooth; Paul W G Elbers; Pedro Povoa; Rui Morais; Despoina Koulenti; Sameer Jog; Nathan Nielsen; Alasdair Jubb Journal: Crit Care Date: 2022-08-03 Impact factor: 19.334